PhD Supervisor: Prof. Dr. Chiara Bolego Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
Modulation of macrophage polarization by 17beta-estradiol
Macrophages are an essential component of innate immunity and play a central role in inflammation and host defense. Cells of the monocyte-macrophage lineage are characterized by considerable diversity and plasticity (1). It’s well established that monocytes and macrophages exist in at least two distinct phenotypes of differentiation/activation: classical/proinflammatory (M1) and alternative/anti-inflammatory (M2). Their activation state can be influenced by a variety of cytokines and microbial products (2); 17β-estradiol (E2) is known to mediate profound effects on monocyte and macrophage immune function (3,4) acting through estrogen receptors (ER). Data from our laboratory demonstrated that ERα mediates most of the beneficial effects of estrogens in the cardiovascular system (5).
Bone marrow-derived macrophages (BMM) will be obtained from tibias and femurs of wild type and estrogen receptor alfa knock out (ERKO) mice. Bone marrow cavities will be flushed with complete medium (RPMI 1640; 11,2 mmol/L glucose) and cells recovered by centrifugation at 400xg for 5 min and will be plated in 6-well plates at 2x106 per well in RPMI supplemented with either M-CSF or GM-CSF for 6 days, to promote cell differentiation. At day 6 medium will be switched to low-glucose (5,5mmol/L) DMEM with 30% L-conditioned, at the following day macrophages will be activated for 4 to 48 hours using either LPS (5ng/ml) and IFNγ (12ng/ml) for M1 polarization, or IL-4 (10ng/ml) plus IL-13 (5ng/ml) for M2 polarization, according to the protocol by Odegaard et al (2008).
This study is aimed at studying the effects of E2 on bone marrow-derived macrophages subsets, in resting state and after M1 or M2 polarization. So, the ImmunoTools IT-Box-Cy55M
would be of great benefit to this project as it would be used to correctly differentiate cells, which in turn will be used to assess expression of surface antigens for classical and alternative phenotype and to determine intracellular cytokines production by flow cytometry.
1. Mantovani A. Macrophage plasticity and polarization: in vivo veritas.
2. Murray PJ, Wynn T. Protective and pathogenic functions of macrophage subsets. Nat Rev
3. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update
4. Harkonen PL, Vaananen HK. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci
2006; 1089: 218-227.
5. Cignarella A, Kratz M, Bolego C. Emerging role of estrogen in the control of cardiometabolic disease. Trends Pharmacol Sci
Mechanisms of macrophage activation in obesity-induced insulin resistance.2008; 11:619-26
for Alice Toniolo
rm EGF, rm Eotaxin / CCL11, rm FGF-a / FGF-1, rm FGF-b / FGF-2, rm FGF-8, rm Flt3L / CD135, rm G-CSF, rm GM-CSF, rm GRO-a / CXCL1, rm GRO-b / CXCL2, rm IFNgamma, rm IL-1alpha, rm IL-1beta, rm IL-2, rmIL-3, rm IL-4, rm IL-5, rm IL-6, rm IL-7, rm IL-9, rm IL-10, rm IL-11, rm IL-13, rm IL-15, rm IL-16, rm IL-17A, rm IL-17C, rm IL-17F, rm IL-19, rm IL-20, rm IL-21, rm IL-22, rm IL-25 / IL-17E, rm IL-27, rm IL-31, rm IL-33, rm IP-10 / CXCL10, rm LIF, rm MCP1 / CCL2, rm M-CSF, rm MIP-1α/ CCL3, rm MIP-1β / CCL4, rm MIP3α / CCL20, rm MIP3β / CCL19, rm NGF-beta, rm PDGF-AA, rm PDGF-BB, rm RANTES / CCL5, rm sCD40L / CD154, rm SCF, rm SDF-1α / CXCL12a, rm SDF-1β / CXCL12b, rm TNFα, rm TPO, rm VEGF
Landesarbeitsgemeinschaft Gesundheit und Soziales NRW Protokoll LAG Gesundheit und Soziales Termin: Samstag,22.09.2012.2012 11:00 – 16:30 UhrOrt: LINKES Zentrum Oberhausen, Elsässer Str. 19, 46045 Oberhausen Teilnehmer/innen Vili Baßnik , Elke Eisenburger, Peter Esser, Rolf Fahnenbruck , Sylvia von Höfen, Rolf Kohn, Werner Rejek, Gast: Angela Spelsberg, Vorstandsmitglied bei Tran
P A A C T , I N C . P R O S T A T E C A N C E R C O M M U N I C A T I O N N E W S L E T T E R • V O L U M E 2 2 , N U M B E R 1 • M a r c h 2 0 0 6FOUNDER: LLOYD J. NEY, SR. – FOUNDED 1984 VACCINE FOR PROSTATE CANCER President and Chairperson: Board of Directors: Shortcomings of current prostate cancer treatment Roughly 30-40% of patients who initially present with prostate c